Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02249169 · ClinicalTrials.gov registry record
Developing Novel Microbiota-Targeted Therapies for Irritable Bowel Syndrome
A clinical trial, sponsored by Mayo Clinic.
- Completed
- Registry status
- 84
- Enrollment target
NCT02249169: Completed study, sponsored by Mayo Clinic.
NCT02249169 is a clinical trial that has completed, run by Mayo Clinic. The registered enrollment target is 84 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02249169 has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- 84 participants
- Enrollment target
Study Summary
This longitudinal study is being done to understand mechanisms underlying development of irritable bowel syndrome (IBS) and the role of the gut bacteria in development of symptoms. This information will be used to determine whether temporal changes in gut microbial taxonomy and metabolism are associated with changes in symptom severity in IBS, and if targeted dietary interventions, including prebiotics, can reverse or moderate these changes.
Primary Outcome
Participants will provide a stool sample at baseline and at periodic intervals for 6 months to assess gut microbial composition.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 84 participants |
| Start Date | 2014-09-19 |
| Est. Completion | 2017-02-08 |
What the finished NCT02249169 record still lists
NCT02249169 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 84 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT02249169 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02249169 about?
NCT02249169 is a clinical study titled "Developing Novel Microbiota-Targeted Therapies for Irritable Bowel Syndrome". This longitudinal study is being done to understand mechanisms underlying development of irritable bowel syndrome (IBS) and the role of the gut bacteria in development of symptoms. This information will be used to determine whether temporal changes in gut microbial taxonomy and metabolism are associ...
What is the current status of trial NCT02249169?
This trial is currently completed. The enrollment target is 84 participants. The study started on 2014-09-19. Estimated completion is 2017-02-08.
Who is sponsoring clinical trial NCT02249169?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02391519 · 84 participants
Effects of High Altitude on AMPK Activation
- NCT03838536 · 84 participants · NA
Synergistic Activity of Human Milk Nutrients and Infant Cognition
- NCT03884075 · 84 participants · Phase 2
Non-Alcoholic Fatty Liver Disease, the HEpatic Response to Oral Glucose, and the Effect of Semaglutide (NAFLD HEROES)
- NCT03894917 · 84 participants
Characterizing Disease Biology, Treatment and Toxicity in Older Adults With Hepatocellular Carcinoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI